Comprehensive analysis of ICICI Pru Nifty Pharma Index Fund-Reg (IDCW) (43467) providing detailed insights into fund performance, portfolio holdings, risk metrics, expense ratios, and investment recommendations.
ICICI Prudential Asset Management Co Ltd
The objective of the Scheme is to invest in companies whose securities are included in Nifty Pharma Index and subject to tracking errors, to endeavor to achieve the returns of the above index. This would be done by investing in all the stocks comprising the Nifty Pharma Index in the same weightage that they represent in Nifty Pharma Index. However, there is no assurance or guarantee that the investment objective of the scheme shall be achieved.
A comprehensive at-a-glance view of key mutual fund health indicators
Good Returns
High Risk
Low Expense Ratio
Equity Focused
Established Team
Average Quality
Showing 1Y NAV history
Performance across different time periods
Fund shows mixed signals. Consider your investment timeline and risk tolerance.
Review detailed analysis and consider dollar-cost averaging through SIPs.
Fund shows mixed signals. Consider your investment timeline and risk tolerance.
Review detailed analysis and consider dollar-cost averaging through SIPs.
Historical performance consistency
Recent performance momentum
Market exposure level
Outperformance vs benchmark
Fund management costs
Fund manager experience
Risk-adjusted returns
Assets under management
This fund has underperformed its benchmark by 1.37% over the 3Y period.
See how your money can grow and compare with popular investment options
Disclaimer: Returns are illustrative and based on assumed rates. Mutual fund investments are subject to market risk. Please read scheme documents carefully.
| Company | Sector | % Assets |
|---|---|---|
| Sun Pharmaceutical Industries Ltd | Pharmaceuticals | 22.86% |
| Sun Pharmaceutical Industries Ltd | Pharmaceuticals | 22.49% |
| Divis Laboratories Ltd | Pharmaceuticals | 10.94% |
| Cipla Ltd | Pharmaceuticals | 10.71% |
| Cipla Ltd | Pharmaceuticals | 10.69% |
| Divis Laboratories Ltd | Pharmaceuticals | 10.24% |
| Dr Reddys Laboratories Ltd | Pharmaceuticals | 9.88% |
| Dr Reddys Laboratories Ltd | Pharmaceuticals | 9.45% |
| Lupin Ltd | Pharmaceuticals | 5.93% |
| Lupin Ltd | Pharmaceuticals | 5.70% |
Compare against Index Fund category average
This comparison shows how the fund performs relative to the Index Fund category average. Positive values indicate outperformance, while negative values show underperformance.
Compare with similar funds in Index Fund category
| Fund Name | NAV | 3M | 6M | 1Y |
|---|---|---|---|---|
| Invesco India Nifty G-sec Sep 2032 Index Fund-Dir (IDCW) | ₹1233.29 | 2.98% | 6.17% | 11.30% |
| Invesco India Nifty G-sec Sep 2032 Index Fund-Dir (G) | ₹1233.29 | 2.98% | 6.17% | 11.30% |
| Invesco India Nifty G-sec Sep 2032 Index Fund-Reg (G) | ₹1229.16 | 2.94% | 6.09% | 11.14% |
| Invesco India Nifty G-sec Sep 2032 Index Fund-Reg (IDCW) | ₹1229.15 | 2.94% | 6.09% | 11.14% |
| Invesco India Nifty G-sec Jul 2027 Index Fund-Dir (G) | ₹1199.62 | 2.73% | 4.94% | 9.12% |
| Invesco India Nifty G-sec Jul 2027 Index Fund-Dir (IDCW | ₹1199.62 | 2.73% | 4.94% | 9.12% |
| Invesco India Nifty G-sec Jul 2027 Index Fund-Reg (IDCW) | ₹1195.53 | 2.69% | 4.86% | 8.96% |
| Invesco India Nifty G-sec Jul 2027 Index Fund-Reg (G) | ₹1195.51 | 2.69% | 4.86% | 8.96% |
| HDFC BSE Sensex Index Fund - Direct | ₹790.24 | 10.66% | 7.25% | 6.29% |
| HDFC BSE Sensex Index Fund - Regular | ₹771.61 | 10.61% | 7.17% | 6.12% |
A seasoned investment professional with over 3 years of experience in equity research and fund management. Known for consistent performance and a disciplined investment approach focused on quality growth stocks.